Literature DB >> 19168514

Self-assessment of health status is associated with inflammatory activation and predicts long-term outcomes in chronic heart failure.

John T Parissis1, Maria Nikolaou, Dimitrios Farmakis, Ioannis A Paraskevaidis, Vassiliki Bistola, Koula Venetsanou, Dimitrios Katsaras, Gerasimos Filippatos, Dimitrios T Kremastinos.   

Abstract

AIMS: Clinicians lack a generally accepted means for health status assessment in chronic heart failure (CHF). We investigated the correlation between health status and inflammation burden as well as its long-term prognostic value in CHF outpatients. METHODS AND
RESULTS: Kansas City Cardiomyopathy Questionnaires (KCCQ) were completed by 137 CHF outpatients (aged 64+/-12 years, mean ejection fraction 27+/-7%). Inflammatory markers [interleukin (IL)-6, IL-10, TNF-alpha, soluble Fas, Fas ligand, ICAM-1, VCAM-1], plasma B-type natriuretic peptide (BNP), 6 min walk test (6MWT), Zung self-rating depression scale, and Beck Depression Inventory were also assessed. Patients were followed for major cardiovascular events (death or hospitalization for disease progression) for up to 250 days. Patients with worse KCCQ-summary (KCCQ-s<50) score had lower 6MWT (P<0.05), and higher BNP (P<0.05) and pro-inflammatory markers (P<0.05) than those with KCCQ-s>or=50. Worse health status was also associated with shorter event-free survival (115+/-12 days for KCCQ-s<50 vs. 214+/-15 days for KCCQ-s>or=50, P=0.0179). Separating patients according KCCQ-functional score (KCCQ-f, cut-off 50) showed similar results. In multivariate Cox regression analysis, only LVEF (HR=0.637, 95% CI 0.450-0.900, P=0.011) and KCCQ-f (HR=0.035, 95% CI 0.002-0.824, P=0.037) were independent predictors of event-free survival at 250 days.
CONCLUSION: KCCQ-s reflects neurohormonal and inflammatory burden in CHF. Among studied questionnaires, only KCCQ-f is an independent predictor of long-term event-free survival in CHF.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19168514      PMCID: PMC2639408          DOI: 10.1093/eurjhf/hfn032

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  26 in total

1.  Self-rating depression scale in an outpatient clinic. Further validation of the SDS.

Authors:  W W Zung; C B Richards; M J Short
Journal:  Arch Gen Psychiatry       Date:  1965-12

Review 2.  A glossary of circulating cytokines in chronic heart failure.

Authors:  S Adamopoulos; J T Parissis; D T Kremastinos
Journal:  Eur J Heart Fail       Date:  2001-10       Impact factor: 15.534

3.  Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure.

Authors:  C P Green; C B Porter; D R Bresnahan; J A Spertus
Journal:  J Am Coll Cardiol       Date:  2000-04       Impact factor: 24.094

4.  Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators.

Authors:  M R Bristow; E M Gilbert; W T Abraham; K F Adams; M B Fowler; R E Hershberger; S H Kubo; K A Narahara; H Ingersoll; S Krueger; S Young; N Shusterman
Journal:  Circulation       Date:  1996-12-01       Impact factor: 29.690

5.  Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group.

Authors:  W S Colucci; M Packer; M R Bristow; E M Gilbert; J N Cohn; M B Fowler; S K Krueger; R Hershberger; B F Uretsky; J A Bowers; J D Sackner-Bernstein; S T Young; T L Holcslaw; M A Lukas
Journal:  Circulation       Date:  1996-12-01       Impact factor: 29.690

6.  Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise.

Authors:  M Packer; W S Colucci; J D Sackner-Bernstein; C S Liang; D A Goldscher; I Freeman; M L Kukin; V Kinhal; J E Udelson; M Klapholz; S S Gottlieb; D Pearle; R J Cody; J J Gregory; N E Kantrowitz; T H LeJemtel; S T Young; M A Lukas; N H Shusterman
Journal:  Circulation       Date:  1996-12-01       Impact factor: 29.690

7.  Clinical and prognostic implications of self-rating depression scales and plasma B-type natriuretic peptide in hospitalised patients with chronic heart failure.

Authors:  J T Parissis; M Nikolaou; D Farmakis; V Bistola; I A Paraskevaidis; S Adamopoulos; G Filippatos; D T Kremastinos
Journal:  Heart       Date:  2007-08-29       Impact factor: 5.994

8.  Development and testing of a new measure of health status for clinical trials in heart failure.

Authors:  G H Guyatt; S Nogradi; S Halcrow; J Singer; M J Sullivan; E L Fallen
Journal:  J Gen Intern Med       Date:  1989 Mar-Apr       Impact factor: 5.128

9.  Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure.

Authors:  Alan S Maisel; Padma Krishnaswamy; Richard M Nowak; James McCord; Judd E Hollander; Philippe Duc; Torbjørn Omland; Alan B Storrow; William T Abraham; Alan H B Wu; Paul Clopton; Philippe G Steg; Arne Westheim; Catherine Wold Knudsen; Alberto Perez; Radmila Kazanegra; Howard C Herrmann; Peter A McCullough
Journal:  N Engl J Med       Date:  2002-07-18       Impact factor: 91.245

10.  Prognostic value of health status in patients with heart failure after acute myocardial infarction.

Authors:  Gabriel E Soto; Philip Jones; William S Weintraub; Harlan M Krumholz; John A Spertus
Journal:  Circulation       Date:  2004-07-19       Impact factor: 29.690

View more
  22 in total

1.  Should patients perception of health status be integrated in the prognostic assessment of heart failure patients? A prospective study.

Authors:  Paola Di Giulio
Journal:  Qual Life Res       Date:  2013-08-04       Impact factor: 4.147

2.  Metabolomic differences in heart failure patients with and without major depression.

Authors:  David C Steffens; K Ranga R Krishnan; Edward D Karoly; Matthew W Mitchell; Christopher M O'Connor; Rima Kaddurah-Daouk
Journal:  J Geriatr Psychiatry Neurol       Date:  2010-01-25       Impact factor: 2.680

3.  Physiological and Psychological Stress in Patients Living With a Left Ventricular Assist Device.

Authors:  Martha Abshire; Julie T Bidwell; Gayle Page; Chakra Budhathoki; Patricia M Davidson; Stuart D Russell; Hae-Ra Han; Shashank Desai; Cheryl Dennison Himmelfarb
Journal:  ASAIO J       Date:  2018 Nov/Dec       Impact factor: 2.872

4.  Pre-operative health status and outcomes after continuous-flow left ventricular assist device implantation.

Authors:  Kelsey M Flint; Daniel D Matlock; Kartik S Sundareswaran; Joann Lindenfeld; John A Spertus; David J Farrar; Larry A Allen
Journal:  J Heart Lung Transplant       Date:  2013-10-08       Impact factor: 10.247

5.  Comparison of the Kansas City Cardiomyopathy Questionnaire and Minnesota Living With Heart Failure Questionnaire in Predicting Heart Failure Outcomes.

Authors:  Derek Yee; Eric Novak; Anne Platts; Michael E Nassif; Shane J LaRue; Justin M Vader
Journal:  Am J Cardiol       Date:  2018-12-04       Impact factor: 2.778

6.  Depressive symptoms, health-related quality of life, and cardiac event-free survival in patients with heart failure: a mediation analysis.

Authors:  Kyoung Suk Lee; Terry A Lennie; Jia-Rong Wu; Martha J Biddle; Debra K Moser
Journal:  Qual Life Res       Date:  2014-02-01       Impact factor: 4.147

7.  Kansas City Cardiomyopathy Questionnaire Score Is Associated With Incident Heart Failure Hospitalization in Patients With Chronic Kidney Disease Without Previously Diagnosed Heart Failure: Chronic Renal Insufficiency Cohort Study.

Authors:  Rakesh K Mishra; Wei Yang; Jason Roy; Amanda H Anderson; Nisha Bansal; Jing Chen; Christopher DeFilippi; Patrice Delafontaine; Harold I Feldman; Radhakrishna Kallem; John W Kusek; Claudia M Lora; Sylvia E Rosas; Alan S Go; Michael G Shlipak
Journal:  Circ Heart Fail       Date:  2015-05-18       Impact factor: 8.790

Review 8.  Hypothalamic dysfunction in heart failure: pathogenetic mechanisms and therapeutic implications.

Authors:  Antonios Rigas; Dimitrios Farmakis; Georgios Papingiotis; Georgios Bakosis; John Parissis
Journal:  Heart Fail Rev       Date:  2018-01       Impact factor: 4.214

Review 9.  Targeting BNIP3 in inflammation-mediated heart failure: a novel concept in heart failure therapy.

Authors:  Patrick Asare Fordjour; Lingyang Wang; Hui Gao; Lan Li; Yadong Wang; Makafui Nyagblordzro; Kojo Agyemang; Guanwei Fan
Journal:  Heart Fail Rev       Date:  2016-09       Impact factor: 4.214

10.  Comparable performance of the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with preserved and reduced ejection fraction.

Authors:  Susan M Joseph; Eric Novak; Suzanne V Arnold; Philip G Jones; Himad Khattak; Anne E Platts; Victor G Dávila-Román; Douglas L Mann; John A Spertus
Journal:  Circ Heart Fail       Date:  2013-10-15       Impact factor: 8.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.